Table 3. Incidence and distribution of LAIP and BCR-ABL and IK6 variants in 106 B-ALL patients.
| LAIPs | Number of patients (%) |
B-ALL subtypes (n=106) |
BA fusion gene (n=95) |
IK6 variant of IKZF1 gene (n=65) |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pro-B ALL | Common-B ALL | Pre-B ALL | Mature-B ALL | BA+a (n=31) | BA− (n=64) | P-value | IK6+b (n=15) | IK6− (n=50) | P-value | ||
| Cross-lineage antigen expression | |||||||||||
| CD13+ | 26/106 (24.5) | 6 | 18 | 2 | 0 | 8 | 14 | 0.670 | 2 | 12 | 0.601 |
| CD33+ | 42/106 (39.6) | 10 | 32 | 0 | 0 | 17 | 22 | 0.057 | 8 | 20 | 0.360 |
| CD15 or CD65+ | 16/106 (15.1) | 10 | 4 | 2 | 0 | 2 | 12 | 0.202 | 2 | 3 | 0.325 |
| CD66c+ | 53/106 (50.0) | 6 | 43 | 3 | 1 | 23 | 26 | 0.002 | 12 | 24 | 0.059 |
| CD13+CD33+ | 19/106 (17.9) | 5 | 14 | 0 | 0 | 6 | 11 | 0.796 | 1 | 10 | 0.415 |
| CD13+CD66c+ | 11/106 (10.4) | 3 | 8 | 0 | 0 | 4 | 5 | 0.674 | 2 | 5 | 1.000 |
| CD33+CD66c+ | 25/106 (23.6) | 3 | 22 | 0 | 0 | 14 | 9 | 0.001 | 7 | 9 | 0.024 |
| CD13+CD33+CD66c+ | 7/106 (6.6) | 2 | 5 | 0 | 0 | 3 | 3 | 0.388 | 1 | 3 | 1.000 |
| Asynchronous antigen expression | |||||||||||
| CD20+CD34+ | 16/106 (15.1) | 4 | 9 | 2 | 1 | 4 | 11 | 0.813 | 3 | 7 | 0.875 |
| CD20+CD10+ | 8/106 (7.5) | 1 | 5 | 0 | 2 | 3 | 5 | 1.000 | 1 | 4 | 1.000 |
| Antigen dim/st expression | |||||||||||
| CD38dimc | 66/106 (62.3) | 13 | 48 | 5 | 0 | 29 | 30 | <0.001 | 12 | 28 | 0.170 |
| CD19dim | 5/106 (4.7) | 2 | 1 | 1 | 1 | 0 | 4 | 0.300 | 1 | 1 | 0.411 |
| CD34dim | 13/106 (12.3) | 3 | 10 | 0 | 0 | 7 | 3 | 0.021 | 2 | 7 | 1.000 |
| CD10dim | 24/106 (22.6) | 5 | 16 | 3 | 0 | 6 | 14 | 0.778 | 4 | 10 | 0.847 |
| CD45dim | 45/106 (42.5) | 5 | 35 | 5 | 0 | 16 | 25 | 0.247 | 8 | 20 | 0.360 |
| CD58std | 54/106 (50.9) | 11 | 32 | 9 | 2 | 13 | 35 | 0.244 | 6 | 28 | 0.277 |
| CD19st | 40/106 (37.7) | 12 | 25 | 2 | 1 | 15 | 22 | 0.189 | 8 | 17 | 0.177 |
| CD34st | 20/106 (18.9) | 6 | 13 | 1 | 0 | 5 | 14 | 0.512 | 5 | 5 | 0.028 |
| CD10st | 16/106 (15.1) | 0 | 14 | 1 | 1 | 5 | 9 | 0.790 | 3 | 7 | 0.875 |
| Ectopic phenotype | |||||||||||
| NG2+ e | 11/106 (10.4) | 10 | 1 | 0 | 0 | 0 | 8 | 0.050 | 1 | 1 | 0.411 |
Abbreviations: BA, BCR-ABL; B-ALL, B-lineage acute lymphoblastic leukemia; LAIP, leukemia-associated immunophenotype.
a
BCR-ABL positive.
b
IK6 variant of IKZF1 gene.
c
Dim expression.
d
Strong expression.
e
Human homologue of the rat chondroitin sulfate proteoglycan NG2.